三生國健(688336.SH)上半年營收達3.41億元 經營性現金流大幅轉正
格隆匯8月24日丨三生國健(688336.SH)披露2022年半年度報吿，報吿期內，公司實現營業收入3.41億元；經營活動現金淨流入1.11億元，而上年同期為淨流出1.72億元。
公司主要收入與利潤來源於具有自主知識產權的主打產品“重組人II型腫瘤壞死因子受體抗體融合蛋白”(商品名“益賽普”)的境內外銷售。益賽普可用於治療類風濕關節炎、強直性脊柱炎和銀屑病，是中國首個上市的全人源抗體類藥物，是中國風濕病領域第一個上市的腫瘤壞死因子(TNF-α)抑制劑，填補了國內企業在全人源治療性抗體類藥物的空白，上市以來累計惠及強直性脊柱炎及類風濕關節炎患者數十萬人。根據IQVIA數據，按銷售額計算，2022年上半年益賽普在國內TNF-α抑制劑市場的份額約為28.2%。
公司自主研發的“重組抗CD25人源化單克隆抗體注射液”(商品名“健尼哌”)，是目前國內唯一獲批上市的人源化抗CD25單抗，已於2019年6月獲得國家藥品監督管理局頒發的藥品GMP證書，並於2019年10月開始上市銷售。該產品可用於預防腎移植引起的急性排斥反應，可與常規免疫抑制方案聯用，能顯著提高移植器官存活率，改善患者生存質量。
賽普汀®(伊尼妥單抗)是中國第一個獲批上市的Fc段修飾，生產工藝優化的創新抗HER2單抗，與化療藥物聯合，已被證明可以延緩HER2陽性的轉移性乳腺癌患者病情進展，並帶來生存獲益。作為國家“十二五”生物製藥重大專項項目，賽普汀®於2020年6月獲得NMPA批准上市。2020年12月底，賽普汀®通過了醫保談判，首次被納入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2020年版)》。伊尼妥單抗在《CSCO乳腺癌診療指南(2022版)》中被列為HER2陽性晚期乳腺癌患者抗HER2治療的I級推薦用藥，肯定了伊尼妥單抗與曲妥珠單抗在轉移性乳腺癌中的同等治療地位，成為晚期乳腺癌全程抗HER2治療的基礎藥物。
目前，公司擁有16個處於不同開發階段、涵蓋腫瘤、自身免疫性及眼科等疾病領域的在研抗體藥物，其中大部分在研藥物為治療用生物製品1類，部分在研藥物為中美雙報。
未來，公司將進一步發揮研發、生產、銷售、質量管理等多方面的綜合競爭優勢，積極推動抗體藥物儲備產品的產業化與臨牀應用，形成多梯隊、高臨牀價值與具備核心競爭力的產品結構，為包括自身免疫性疾病、腫瘤等患者提供高品質、安全有效的臨牀解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
